EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A functional comparison of readthrough agent ELX-02 across a wide range of nonsense CFTR variants

Marlies Destoop, Anabela S Ramalho, Iris A L Silva, Annelotte M Vonk, Sylvia Suen, Marlou C Bierlaagh, Sylvia F Boj, Robert G J Vries, Jeffrey M Beekman, Kris De Boeck, Cornelis K van der Ent, Margarida D Amaral und 3 weitere

Journal of Cystic Fibrosis · 2026-09

DOI: 10.1016/j.jcf.2026.09.004 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cystic Fibrosis, 2026-09. Verfasst von Marlies Destoop und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Pediatric Pulmonology, Wilhelmina Children's Hospital, University Medical Center Utrecht, UMC Utrecht, Lundlaan 6, 3584 EA,…. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Horizon 2020 Framework Programme, Horizon 2020.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Nonsense variants in CFTR account for ∼10% of cystic fibrosis (CF) variants and cannot be treated with available CFTR modulators. Translational readthrough agents such as ELX-02 offer a potential therapeutic strategy for CFTR nonsense variants, but clinical trials, conducted primarily in individuals carrying the G542X variant, have demonstrated limited efficacy. Our study aimed to evaluate ELX-02-mediated CFTR rescue across a broad range of nonsense variants using patient-derived intestinal organoids (PDIOs) to define variant-specific determinants of readthrough efficacy and assess its potential across a genetically diverse CF population. METHOD: The ex vivo response to ELX-02 was assessed in 206 PDIOs carrying heterogeneous nonsense variants. CFTR function was quantified using the forskolin-induced swelling (FIS) assay after 48-hour exposure to ELX-02. Responses were analysed by genotype and stop codon identity, with secondary validation performed in a selected subset of PDIOs (n = 60). RESULTS: ELX-02-mediated CFTR rescue varied markedly, ranging from responses approaching those observed with approved CFTR modulators (LUM/IVA) to responses at or below detection limit. Overall, maximal responses were modest and at the lower end of the functional range for CFTR modulators. Rescue was dose-dependent and higher in PDIOs carrying two nonsense variants when compared with PDIOs carrying a single nonsense variant combined with a residual or minimal function variant. Nonsense variants in nucleotide-binding domain 1, including G542X, S466X, G550X and R553X, showed relatively higher responsiveness. CONCLUSION: ELX-02 induces limited and highly heterogeneous CFTR rescue across nonsense variants. PDIO-based functional screening provides a framework to guide patient selection and stratification for future readthrough therapy trials.

Schlagwörter

Stichwörter der Autor:innen

ELX-02Forskolin-induced swelling assayPatient-derived intestinal organoidsPremature termination codonReadthrough therapy

Autor:innen und Institutionen

  • Department of Pediatrics, Pediatric Pulmonology, Wilhelmina Children's Hospital, University Medical Center Utrecht, UMC Utrecht, Lundlaan 6, 3584 EA, Utrecht, the Netherlands.
  • CF research lab, Woman and Child Unit, Department of Development and Regeneration, KU Leuven, Herestraat 49, 3000, Leuven, Belgium.
  • BioISI - Biosystems & Integrative Sciences Institute, Faculty of Sciences, University of Lisboa, Campo Grande C8 bdg, 1749-016, Lisboa, Portugal.
  • Lab of Cellular Disease Models, Department of Pediatrics, Regenerative Medicine Center Utrecht, UMC Utrecht, Uppsalalaan 8, 3584 CT, Utrecht, the Netherlands.
  • HUB Organoids B.V. (HUB), Yalelaan 62, 3584 CM, Utrecht, the Netherlands.
  • Department of Pediatrics, Pediatric Pulmonology, UZ Leuven, Herestraat 49, 3000, Leuven, Belgium.

Förderung

  • Horizon 2020 Framework Programme
  • Horizon 2020

Zitieren

APA

Destoop, M., Ramalho, A. S., Silva, I. A. L., Vonk, A. M., Suen, S., Bierlaagh, M. C., Boj, S. F., Vries, R. G. J., Beekman, J. M., De Boeck, K., van der Ent, C. K., Amaral, M. D., Vermeulen, F., Spelier, S., & HIT-CF Organoid Study Group (2026). A functional comparison of readthrough agent ELX-02 across a wide range of nonsense CFTR variants. Journal of Cystic Fibrosis. https://doi.org/10.1016/j.jcf.2026.09.004

Vancouver

Destoop M, Ramalho AS, Silva IAL, Vonk AM, Suen S, Bierlaagh MC, et al. A functional comparison of readthrough agent ELX-02 across a wide range of nonsense CFTR variants. Journal of Cystic Fibrosis. 2026. doi:10.1016/j.jcf.2026.09.004

BibTeX
@article{Destoop2026,
  author = {Destoop, Marlies and Ramalho, Anabela S and Silva, Iris A L and Vonk, Annelotte M and Suen, Sylvia and Bierlaagh, Marlou C and Boj, Sylvia F and Vries, Robert G J and Beekman, Jeffrey M and De Boeck, Kris and van der Ent, Cornelis K and Amaral, Margarida D and Vermeulen, Francois and Spelier, Sacha and HIT-CF Organoid Study Group, HIT-CF Organoid Study Group},
  title = {A functional comparison of readthrough agent ELX-02 across a wide range of nonsense CFTR variants},
  journal = {Journal of Cystic Fibrosis},
  year = {2026},
  doi = {10.1016/j.jcf.2026.09.004}
}
Kostenlos starten →